Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—Rapid genome sequencing in neonatal intensive care units is a complex process involving a multidisciplinary team, including pathologists, genetic counselors, and clinicians. The goal is to identify genetic causes of complex medical conditions in newborns, often born prematurely with multiple health issues.
February 2026—At the USCAP 2026 meeting, two guidelines on gastrointestinal pathology biomarkers will be presented. The updated guideline on HER2 testing in gastroesophageal adenocarcinoma reaffirms IHC with follow-up ISH as the best method for …
February 2026—The 2025 accreditation checklist edition, released December 9, includes revisions to address the use of digital pathology platforms in laboratories.
February 2026—The 2024 revision of the 2017 McDonald criteria for diagnosing multiple sclerosis allows the kappa-free light chain index to replace oligoclonal band detection in cerebrospinal fluid analysis.
February 2026—Washington University in St. Louis implemented a clinical decision support intervention to reduce unnecessary magnesium testing.
February 2026—A six-year-old boy presented with abdominal pain and was found to have a large mediastinal mass. Biopsy revealed a spindle cell sarcoma, and molecular testing identified an NTRK1 rearrangement, confirming the diagnosis of NTRK1-rearranged spindle cell sarcoma.
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
February 2026—The pathology community must embrace new technologies, such as digital pathology and AI, to avoid being left behind.
February 2026—A study of 42 thrombocytopenic neonates found that platelet transfusions increased platelet counts but did not significantly impact bleeding. Another study investigated the impact of probiotics on gut microbiota after colonoscopy.
February 2026—A study introduced a computational framework to analyze collagen disorder architectural (CoDA) features in colon cancer patients, revealing significant associations with clinical, molecular, and genetic factors. Additionally, a dedicated histopathologic assessment of rituximab-associated CVID-like enteropathy highlighted key histologic features, emphasizing the importance of pathologist awareness of this entity.
